Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

41. Screening for Unhealthy Drug Use: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Full Text available with Trip Pro

Screening for Unhealthy Drug Use: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Illicit drug use is among the most common causes of preventable morbidity and mortality in the US.To systematically review the literature on screening and interventions for drug use to inform the US Preventive Services Task Force.MEDLINE, PubMed, PsycINFO, Embase, and Cochrane Central Register of Controlled Trials through September 18, 2018; literature surveillance through (...) September 21, 2019.Test accuracy studies to detect drug misuse and randomized clinical trials of screening and interventions to reduce drug use.Critical appraisal and data abstraction by 2 reviewers and random-effects meta-analyses.Sensitivity, specificity, drug use and other health, social, and legal outcomes.Ninety-nine studies (N = 84 206) were included. Twenty-eight studies (n = 65 720) addressed drug screening accuracy. Among adults, sensitivity and specificity of screening tools for detecting

2020 JAMA

42. Screening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement. An estimated 12% of adults 18 years or older and 8% of adolescents aged 12 to 17 years report unhealthy use of prescription or illegal drugs in the US.To update its 2008 recommendation, the USPSTF commissioned reviews of the evidence on screening by asking questions about drug use and interventions for unhealthy drug use in adults and adolescents.This recommendation statement applies to adults 18 years (...) certainty that screening by asking questions about unhealthy drug use has moderate net benefit when services for accurate diagnosis of unhealthy drug use or drug use disorders, effective treatment, and appropriate care can be offered or referred. In adolescents, because of the lack of evidence, the USPSTF concludes that the benefits and harms of screening for unhealthy drug use are uncertain and that the balance of benefits and harms cannot be determined.The USPSTF recommends screening by asking

2020 JAMA

43. Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis. (Abstract)

Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis. The Patient Health Questionnaire depression module (PHQ-9) is a 9-item self-administered instrument used for detecting depression and assessing severity of depression. The Patient Health Questionnaire-2 (PHQ-2) consists of the first 2 items of the PHQ-9 (which assess the frequency of depressed mood and anhedonia) and can be used as a first step to identify (...) the clinical and research value of this combined approach to screening.

2020 JAMA

44. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review Full Text available with Trip Pro

AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review - Gastroenterology Go search This Journal Search AGA Journals , P1822-1830, May 01, 2020 Powered By Mendeley Share on AGA Clinical Practice Update on Screening and Surveillance (...) of cirrhosis, is often diagnosed at advanced stages, and is associated with lower receipt of curative therapy and with poorer survival, current society guidelines provide limited guidance/recommendations addressing HCC surveillance in patients with NAFLD outside the context of established cirrhosis. Limited data are presently available to guide clinicians with respect to which patients with NAFLD should undergo HCC surveillance, optimal screening tools, frequency of monitoring, and the influence

2020 American Gastroenterological Association Institute

45. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study

Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health (...) Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul;43(7):1553-1556. doi: 10.2337/dc19-1944. Epub 2020 Apr 28. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Endocrinology, Department of Pediatrics, The Hospital

2020 EvidenceUpdates

46. Hepatitis C Virus Infection in Adolescents and Adults: Screening

Hepatitis C Virus Infection in Adolescents and Adults: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Adults aged 18 to 79 years The USPSTF recommends screening for hepatitis C virus (HCV) infection in adults aged 18 to 79 years. B View the Clinical Summary in What does the USPSTF recommend? For adults aged 18 to 79 years: Grade B Screen adults for hepatitis C virus (HCV) infection. To whom does (...) this recommendation apply? Asymptomatic adults (including pregnant persons) aged 18 to 79 years without known liver disease. What’s new? This recommendation expands the population that should be screened. The USPSTF now recommends that all adults aged 18 to 79 years be screened. Previously, it recommended screening adults born between 1945 and 1965 and others at high risk. How to implement this recommendation? Screen. Screen adults aged 18 to 79 years with anti–HCV antibody testing followed by confirmatory

2020 U.S. Preventive Services Task Force

47. Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK

Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search Considerations (...) relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK Technical report 12 Jun 2020 Cite: European Centre for Disease Prevention and Control. Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19

2020 European Centre for Disease Prevention and Control - Technical Guidance

48. Unhealthy Drug Use: Screening

Unhealthy Drug Use: Screening Recommendation: Unhealthy Drug Use: Screening | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation: Unhealthy Drug Use: Screening Recommendation: Unhealthy Drug Use: Screening Recommendation Summary Population Recommendation Adults age 18 years or older The USPSTF recommends screening by asking questions about unhealthy drug use in adults age 18 years or older. Screening should be implemented when services (...) for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. (Screening refers to asking questions about unhealthy drug use, not testing biological specimens.) B Adolescents The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for unhealthy drug use in adolescents. See the "Practice Considerations" section for suggestions for practice regarding the I statement. I Clinician Summary What does the USPSTF

2020 U.S. Preventive Services Task Force

49. Should temperature screening by thermal imaging systems be part of the policy response to curb COVID-19 transmission?

Should temperature screening by thermal imaging systems be part of the policy response to curb COVID-19 transmission? A Should temperature screening by thermal imaging systems be part of the policy response to curb Covid- 19 transmission? HIS Evidence were asked to examine whether mass screening by thermal imaging systems should feature in local and national strategies being implemented to control Covid-19 transmission. This is to support the work of Public Health Scotland and the Scottish (...) Government. A rapid review of existing guidance and current evidence was undertaken, with the findings summarised in this report. HIS Evidence Conclusion: The evidence on whether screening by thermal imaging systems is effective in controlling infectious disease transmission is weak or inconclusive at best. The most recent review suggested that screening alone or alongside a questionnaire was not effective at detecting infected persons. The evidence on implementation and impact of screening during

2020 Covid-19 Ad hoc papers

50. Fetal anomaly screening programme: standards

Fetal anomaly screening programme: standards Fetal anomaly screening programme: standards - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance and support Guidance Fetal anomaly screening programme: standards Screening standards for the NHS Fetal Anomaly Screening Programme (FASP (...) ). Published 1 January 2015 Last updated 5 June 2020 — From: Documents Ref: PHE publications gateway number: GW-369 HTML HTML Ref: PHE publications gateway number: GW-369 HTML If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details These documents present the national screening standards for the NHS Fetal Anomaly

2020 Public Health England

51. A multi-center evaluation of TECHNOSCREEN((R)) ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13

A multi-center evaluation of TECHNOSCREEN((R)) ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13 A Multi-Center Evaluation of TECHNOSCREEN ® ADAMTS-13 Activity Assay as a Screening Tool for Detecting Deficiency of ADAMTS-13 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes (...) Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Thromb Haemost Actions . 2020 Apr 2. doi: 10.1111/jth.14815. Online ahead of print. A Multi-Center Evaluation of TECHNOSCREEN ® ADAMTS-13 Activity Assay as a Screening Tool for Detecting Deficiency of ADAMTS-13 , , , , , , , , , , , , Affiliations Expand Affiliations 1 Diagnostic Haemostasis and Thrombosis, Viapath Analytics, Guy's & St. Thomas' Hospitals, London, UK. 2

2020 EvidenceUpdates

52. Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. Full Text available with Trip Pro

Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. To evaluate the long term risks of invasive breast cancer and death from breast cancer after ductal carcinoma in situ (DCIS) diagnosed through breast screening.Population based observational cohort study.Data from the NHS Breast Screening Programme and the National Cancer Registration and Analysis (...) Service.All 35 024 women in England diagnosed as having DCIS by the NHS Breast Screening Programme from its start in 1988 until March 2014.Incident invasive breast cancer and death from breast cancer.By December 2014, 13 606 women had been followed for up to five years, 10 998 for five to nine years, 6861 for 10-14 years, 2620 for 15-19 years, and 939 for at least 20 years. Among these women, 2076 developed invasive breast cancer, corresponding to an incidence rate of 8.82 (95% confidence interval 8.45

2020 BMJ

53. Long-Term Colorectal Cancer Incidence and Mortality After a Single Negative Screening Colonoscopy. (Abstract)

Long-Term Colorectal Cancer Incidence and Mortality After a Single Negative Screening Colonoscopy. Current guidelines recommend a 10-year interval between screening colonoscopies, but evidence is limited.To assess the long-term risk for colorectal cancer (CRC) and death from CRC after a high- and low-quality single negative screening colonoscopy.Observational study.Polish Colonoscopy Screening Program.Average-risk individuals aged 50 to 66 years who had a single negative colonoscopy (...) (no neoplastic findings).Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) of CRC after high- and low-quality single negative screening colonoscopy. High-quality colonoscopy included a complete examination, with adequate bowel preparation, performed by endoscopists with an adenoma detection rate of 20% or greater.Among 165 887 individuals followed for up to 17.4 years, CRC incidence (0.28 [95% CI, 0.25 to 0.30]) and mortality (0.19 [CI, 0.16 to 0.21]) were 72% and 81% lower

2020 Annals of Internal Medicine

54. National Clinical Guideline on nutrition screening and oral nutrition support for adults

National Clinical Guideline on nutrition screening and oral nutrition support for adults Gov.ie - Nutrition screening and use of oral nutrition support for adults in the acute care setting A notice about cookies This website uses cookies. Some cookies may have been set already. To find out more about our use of cookies you can visit our Privacy policy. By browsing this website, you agree to our use of cookies. BETA This is a prototype - your will help us to improve it. Collection Nutrition (...) screening and use of oral nutrition support for adults in the acute care setting Published: 20 April 2020 From: Nutrition screening and use of oral nutrition support for adults in the acute care setting Guideline Number: 22 Publication Date: April 2020 Nutrition screening and use of oral nutrition support for adults in the acute care setting - National Clinical Guidleline No. 22 Full Report Nutrition screening and use of oral nutrition support for adults in the acute care setting - National Clinical

2020 HIQA Guidelines

55. Rapid Review: Diabetic retinopathy screening during the COVID-19 pandemic

Rapid Review: Diabetic retinopathy screening during the COVID-19 pandemic Rapid Review: Diabetic retinopathy screening during the COVID-19 pandemic - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Rapid Review: Diabetic retinopathy screening during the COVID-19 pandemic May 12, 2020 Ehtasham Ahmad, Melanie J Davies, Kamlesh Khunti BACKGROUND People with diabetes (PWD) are included in the group (...) at increased risk of severe illness from coronavirus (COVID-19) and have been advised to observe stringent social distancing measures.(1) This creates a difficult situation for PWD and their Health Care Providers (HCP) as PWD require an annual review including retinal screening as part of their screening for complications, which involves a physical visit to a community or hospital facility or an eye clinic. This rapid review addresses the following questions: How can we help stratify annual retinal

2020 Oxford COVID-19 Evidence Service

56. Breast screening: GE Healthcare Senographe Pristina DBT System

Breast screening: GE Healthcare Senographe Pristina DBT System Breast screening: GE Healthcare Senographe Pristina DBT System - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Coronavirus guidance is being updated. Read Stay alert. Control the virus. Save lives. Guidance Breast screening (...) : GE Healthcare Senographe Pristina DBT System Practical evaluation of GE Healthcare Senographe Pristina digital breast tomosynthesis system used in the NHS breast screening programme. Published 21 April 2020 From: Documents Ref: PHE publications gateway number: GW-1125 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you

2020 Public Health England

57. Position Statement on COVID-19 and Acute Heart Failure: screening the critically ill

Position Statement on COVID-19 and Acute Heart Failure: screening the critically ill 1 COVID-19 and acute heart failure: screening the critically ill Sean Lal 1* , Christopher Hayward 2* , Carmine De Pasquale 3 , David Kaye 4 , George Javorsky 5 , Peter Bergin 4 , John Atherton 12 , Marcus Ilton 6 , Robert Weintraub 7 , Priya Nair 2 , Mate Rudas 1 , Lawrence Dembo 10 , Robert Doughty 11 , Gayathri Kumarasinghe 13 , Craig Juergens 13 , Paul Bannon 1 , Nicole Bart 2 , Clara Chow 8 , Jo-Dee (...) /4/20 2 There is a need to screen for acute heart failure in critically ill COVID-19 patients. Up to one- third of COVID-19 patients who are admitted to the ICU, albeit a select population, develop an acute cardiomyopathy [1], which could represent myocarditis or stress cardiomyopathy. Fulminant myocarditis has been identified as a cause of death in younger patients with Middle East Respiratory Syndrome [2], and a similar trend may follow with COVID-19, even though younger age groups comprise

2020 Cardiac Society of Australia and New Zealand

58. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report

Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic CHEST Expert Panel Report Q21 Peter J. Mazzone, MD, MPH, FCCP; Michael K. Gould, MD, FCCP; Douglas A. Arenberg, MD, FCCP; Alexander C. Chen, MD; Humberto K. Choi, MD, FCCP; Frank C. Detterbeck, MD, FCCP; Farhood Farjah, MD, MPH; Kwun M. Fong, MD; Jonathan M. Iaccarino, MD; Samuel M. Janes, PhD; Jeffrey P (...) thathasoccurredtocombatthe pandemic,havealtered thebalance of bene?ts and harms that informed current (pre-COVID-19) guideline recommendations for lung cancer screening and lung nodule evaluation. RESEARCHQUESTION: Q6 Consensus statements were developed to guide clinicians managing lung cancer screening programs and patients with lung nodules during the COVID-19 pandemic. STUDYDESIGNANDMETHODS:Anexpert panelof24members,includingpulmonologists(n¼ 17), thoracic radiologists (n¼ 5), and thoracic surgeons (n¼ 2), was formed

2020 American College of Chest Physicians

59. AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Appropriate.Safe.Affordable © 2019 AIM Specialty Health 2068-0319 Clinical Appropriateness Guidelines Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE MARCH 3, 2020 PROPRIETARY Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2019 Informed Medical Decisions, Inc. All Rights Reserved. 2 Table of Contents (...) Scope 3 Appropriate Use Criteria 3 Carrier Screening for Familial Disease 3 Fragile X 3 Carrier Screening for Common and Ethnic Genetic Diseases 3 Cystic Fibrosis 3 Spinal Muscular Atrophy 4 Hemoglobinopathies 4 Ashkenazi Jewish Carrier Screening 4 Other Ethnicities 5 Carrier Screening Not Clinically Appropriate 5 Preimplantation Genetic Screening and Diagnostic Testing of Embryos 5 Preimplantation Genetic Screening for Common Aneuploidy 6 Prenatal Cell-Free DNA Screening 6 Prenatal Molecular

2020 AIM Specialty Health

60. Effect of a Mammography Screening Decision Aid for Women 75 Years and Older: A Cluster Randomized Clinical Trial

Effect of a Mammography Screening Decision Aid for Women 75 Years and Older: A Cluster Randomized Clinical Trial Effect of a Mammography Screening Decision Aid for Women 75 Years and Older: A Cluster Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine (...) JAMA Intern Med Actions . 2020 Apr 20;e200440. doi: 10.1001/jamainternmed.2020.0440. Online ahead of print. Effect of a Mammography Screening Decision Aid for Women 75 Years and Older: A Cluster Randomized Clinical Trial , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of General Medicine, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 2 Division of Geriatric Medicine, Department of Medicine, The University

2020 EvidenceUpdates